• Consensus Rating: Buy
  • Consensus Price Target: $207.15
  • Forecasted Upside: 48.55%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$139.45
▼ -1.51 (-1.07%)

This chart shows the closing price for BNTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioNTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTX

Analyst Price Target is $207.15
▲ +48.55% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for BioNTech in the last 3 months. The average price target is $207.15, with a high forecast of $300.00 and a low forecast of $148.00. The average price target represents a 48.55% upside from the last price of $139.45.

This chart shows the closing price for BNTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in BioNTech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2023UBS GroupSet Target$168.00Low
1/31/2023The Goldman Sachs GroupLower TargetNeutral$177.00 ➝ $156.00Low
1/30/2023Berenberg BankSet Target$300.00Low
1/24/2023Morgan StanleyBoost TargetEqual Weight$203.00 ➝ $216.00Low
1/16/2023The Goldman Sachs GroupSet Target$177.00Low
1/11/2023JPMorgan Chase & Co.Set Target$148.00Low
12/15/2022Bank of AmericaUpgradeNeutral ➝ Buy$239.00Low
11/21/2022JPMorgan Chase & Co.Set Target$148.00Low
11/15/2022UBS GroupSet Target$168.00Low
11/8/2022Berenberg BankSet Target$312.00Low
11/8/2022Morgan StanleyBoost TargetEqual Weight$194.00 ➝ $203.00Low
11/8/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$200.00 ➝ $191.00Low
11/8/2022The Goldman Sachs GroupLower TargetNeutral$200.00 ➝ $177.00Low
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$183.00 ➝ $132.00Low
10/21/2022Berenberg BankSet Target$312.00Low
9/27/2022Berenberg BankSet Target$312.00Low
9/8/2022Deutsche Bank AktiengesellschaftSet Target$180.00Low
9/8/2022Berenberg BankSet Target$312.00Low
8/17/2022CowenInitiated CoverageMarket Perform$177.00Low
8/17/2022CowenInitiated CoverageMarket PerformLow
8/10/2022HC WainwrightLower TargetBuy$283.00 ➝ $272.00Low
8/9/2022The Goldman Sachs GroupSet Target$200.00Low
8/9/2022Berenberg BankSet Target$312.00Low
8/9/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$192.00 ➝ $200.00Low
7/29/2022SVB LeerinkBoost TargetOutperform$223.00 ➝ $224.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$195.00 ➝ $194.00Low
7/13/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$253.00 ➝ $223.00Low
7/11/2022HC WainwrightLower TargetBuy$298.00 ➝ $283.00N/A
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$192.00N/A
7/1/2022Deutsche Bank AktiengesellschaftSet Target$180.00Low
6/30/2022The Goldman Sachs GroupSet Target$209.00Low
6/30/2022UBS GroupSet Target$168.00Low
6/15/2022The Goldman Sachs GroupSet Target$206.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$255.00 ➝ $206.00Low
5/11/2022The Goldman Sachs GroupSet Target$255.00Medium
5/10/2022JPMorgan Chase & Co.Set Target$183.00High
5/9/2022Jefferies Financial GroupSet Target$230.00Low
4/12/2022HC WainwrightLower TargetBuy$339.00 ➝ $298.00Medium
4/12/2022Morgan StanleyLower TargetEqual Weight$217.00 ➝ $197.00Low
4/11/2022Berenberg BankReiterated RatingBuy$350.00Low
4/5/2022Canaccord Genuity GroupLower TargetBuy$450.00 ➝ $300.00Medium
4/5/2022UBS GroupLower TargetBuy ➝ Buy$450.00 ➝ $300.00Low
4/5/2022Berenberg BankSet Target$400.00N/A
4/1/2022The Goldman Sachs GroupSet Target$255.00High
4/1/2022Deutsche Bank AktiengesellschaftSet Target$200.00High
3/31/2022JPMorgan Chase & Co.Set Target$183.00Low
3/30/2022Jefferies Financial GroupSet Target$230.00High
3/18/2022Jefferies Financial GroupSet Target$230.00Medium
2/23/2022HC WainwrightLower TargetBuy$366.00 ➝ $339.00High
2/14/2022HC WainwrightReiterated RatingBuy$366.00High
2/1/2022Morgan StanleyLower TargetEqual Weight$284.00 ➝ $217.00Medium
2/1/2022Redburn PartnersUpgradeSell ➝ NeutralLow
1/19/2022HC WainwrightReiterated RatingBuy$366.00High
1/18/2022Morgan StanleyLower TargetEqual Weight$294.00 ➝ $284.00High
1/12/2022The Goldman Sachs GroupSet Target$299.00Low
1/5/2022Berenberg BankSet Target$400.00Low
1/4/2022HC WainwrightReiterated RatingBuy$366.00Medium
12/22/2021UBS GroupUpgradeNeutral ➝ BuyHigh
12/21/2021HC WainwrightBoost TargetBuy$360.00 ➝ $366.00High
12/16/2021Morgan StanleyInitiated CoverageEqual Weight$294.00Medium
12/9/2021Deutsche Bank AktiengesellschaftSet Target$225.00Medium
12/8/2021Berenberg BankSet Target$400.00Low
12/8/2021Jefferies Financial GroupSet Target$230.00Low
12/6/2021Bank of AmericaBoost TargetNeutral ➝ Neutral$341.00 ➝ $349.00High
11/29/2021Berenberg BankSet Target$400.00Low
11/22/2021Jefferies Financial GroupSet Target$230.00High
11/10/2021HC WainwrightUpgradeNeutral ➝ Buy$242.00 ➝ $360.00Medium
11/10/2021JPMorgan Chase & Co.Set Target$180.00Low
11/9/2021Jefferies Financial GroupSet Target$230.00High
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00High
10/7/2021Jefferies Financial GroupSet Target$230.00High
10/6/2021Jefferies Financial GroupInitiated CoverageHold$230.00High
10/5/2021HC WainwrightReiterated RatingHold$330.00Low
10/5/2021Berenberg BankSet Target$400.00Low
10/5/2021SVB LeerinkLower TargetMarket Perform$293.00 ➝ $268.00Low
10/5/2021Bryan, Garnier & CoSet Target$359.00Low
9/29/2021HC WainwrightReiterated RatingHold$330.00Low
9/29/2021The Goldman Sachs GroupSet Target$433.00Low
9/24/2021Bryan, Garnier & CoSet Target$451.00High
9/23/2021UBS GroupSet Target$300.00Low
9/23/2021The Goldman Sachs GroupSet Target$433.00Low
9/21/2021HC WainwrightReiterated RatingHold$330.00Low
8/31/2021HC WainwrightReiterated RatingHold$330.00Medium
8/27/2021UBS GroupBoost TargetNeutral$111.00 ➝ $300.00Medium
8/13/2021SVB LeerinkBoost TargetMarket Perform$159.00 ➝ $293.00Low
8/11/2021HC WainwrightBoost TargetNeutral$194.00 ➝ $330.00High
8/11/2021Bryan, Garnier & CoUpgradeNeutral ➝ BuyHigh
8/8/2021The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
7/22/2021SVB LeerinkReiterated RatingHoldLow
7/20/2021HC WainwrightReiterated RatingHold$194.00High
7/19/2021Wolfe ResearchInitiated CoverageOutperform$248.00High
7/14/2021HC WainwrightReiterated RatingHold$194.00Low
6/23/2021SVB LeerinkReiterated RatingHoldMedium
6/16/2021Redburn PartnersReiterated RatingNeutral ➝ Sell$146.00High
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$173.00Low
5/17/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$135.00 ➝ $206.00N/A
5/11/2021SVB LeerinkBoost TargetPositive ➝ Market Perform$118.00 ➝ $159.00Low
5/11/2021Bryan, Garnier & CoDowngradeBuy ➝ Neutral$135.00 ➝ $206.00Low
4/13/2021SVB LeerinkBoost TargetMarket Perform$110.00 ➝ $118.00High
4/6/2021SVB LeerinkBoost TargetMarket Perform$106.00 ➝ $110.00Low
4/6/2021Berenberg BankSet TargetBuy$130.00Medium
4/6/2021JPMorgan Chase & Co.Set TargetNeutral$104.00Medium
3/31/2021JPMorgan Chase & Co.Reiterated RatingNeutral$104.00Low
3/31/2021Berenberg BankReiterated RatingBuy$130.00Medium
2/4/2021SVB LeerinkBoost TargetMarket Perform$97.00 ➝ $106.00Low
1/11/2021Berenberg BankSet TargetBuy$126.00High
12/15/2020SVB LeerinkBoost TargetMarket Perform$91.00 ➝ $97.00Low
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$123.00 ➝ $126.00High
11/24/2020SVB LeerinkBoost TargetMarket Perform$90.00 ➝ $91.00Low
11/16/2020Berenberg BankReiterated RatingBuy$126.00Medium
11/10/2020JPMorgan Chase & Co.Set TargetNeutral$90.00Medium
11/10/2020SVB LeerinkBoost TargetMarket Perform$64.00 ➝ $90.00High
10/29/2020CommerzbankInitiated CoverageBuy$119.00High
10/14/2020SVB LeerinkBoost TargetPositive ➝ Market Perform$62.00 ➝ $69.00High
9/22/2020Berenberg BankReiterated RatingBuy$98.00Medium
8/6/2020SVB LeerinkBoost TargetMarket Perform$42.00 ➝ $69.00High
8/3/2020Berenberg BankInitiated CoverageBuy$98.00Medium
7/27/2020HC WainwrightReiterated RatingHoldLow
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
7/20/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
7/14/2020HC WainwrightReiterated RatingHoldHigh
7/2/2020Bryan, Garnier & CoBoost Target$50.00 ➝ $62.00High
7/2/2020SVB LeerinkBoost TargetPositive ➝ Market Perform$37.00 ➝ $42.00High
6/30/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
6/25/2020HC WainwrightLower TargetBuy$69.00 ➝ $63.00High
5/19/2020HC WainwrightUpgradeNeutral ➝ Buy$48.00 ➝ $69.00High
4/28/2020Bank of AmericaDowngradeBuy ➝ Neutral$51.00Medium
4/13/2020HC WainwrightReiterated RatingNeutral$30.00 ➝ $48.00High
3/18/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00 ➝ $33.00High
3/17/2020HC WainwrightReiterated RatingHold$30.00High
3/9/2020HC WainwrightInitiated CoverageNeutral$30.00High
1/22/2020UBS GroupDowngradeBuy ➝ Neutral$21.00 ➝ $35.00Medium
11/5/2019Wolfe ResearchInitiated CoverageOutperform$21.00 ➝ $21.00Low
11/4/2019SVB LeerinkInitiated CoverageOutperformHigh
11/4/2019Berenberg BankInitiated CoverageBuy$25.00High
11/4/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
11/4/2019JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
11/4/2019UBS GroupInitiated CoverageBuy$21.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 35 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
7/12/2022
  • 5 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
8/11/2022
  • 7 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
9/10/2022
  • 12 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
10/10/2022
  • 9 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
11/9/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/8/2023
  • 10 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
2/7/2023

Current Sentiment

  • 10 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

BioNTech logo
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Read More

Today's Range

Now: $139.45
Low: $138.87
High: $141.06

50 Day Range

MA: $156.59
Low: $139.94
High: $186.05

52 Week Range

Now: $139.45
Low: $117.08
High: $189.07

Volume

132,391 shs

Average Volume

730,348 shs

Market Capitalization

$33.84 billion

P/E Ratio

3.15

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?

The following Wall Street sell-side analysts have issued reports on BioNTech in the last year: Bank of America Co., Berenberg Bank, Canaccord Genuity Group Inc., Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and UBS Group AG.
View the latest analyst ratings for BNTX.

What is the current price target for BioNTech?

13 Wall Street analysts have set twelve-month price targets for BioNTech in the last year. Their average twelve-month price target is $207.15, suggesting a possible upside of 48.6%. Berenberg Bank has the highest price target set, predicting BNTX will reach $300.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $148.00 for BioNTech in the next year.
View the latest price targets for BNTX.

What is the current consensus analyst rating for BioNTech?

BioNTech currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNTX will outperform the market and that investors should add to their positions of BioNTech.
View the latest ratings for BNTX.

What other companies compete with BioNTech?

Other companies that are similar to BioNTech include Biogen, Seagen, argenx, Bio-Techne and Qiagen. Learn More about companies similar to BioNTech.

How do I contact BioNTech's investor relations team?

BioNTech's physical mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company's listed phone number is 49-61-31908-40 and its investor relations email address is [email protected] The official website for BioNTech is www.biontech.de. Learn More about contacing BioNTech investor relations.